Tighe Reardon's most recent trade in Janux Therapeutics Inc was a trade of 691,525 Common Stock done at an average price of $54.8 . Disclosure was reported to the exchange on June 3, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics Inc | Tighe Reardon | Acting Chief Financial Officer | 03 Jun 2024 | 691,525 | 3,340,018 | - | 54.8 | 37,860,994 | Common Stock | |
| Janux Therapeutics Inc | Tighe Reardon | Acting Chief Financial Officer | 03 Jun 2024 | 131,196 | 633,673 | - | 54.8 | 7,182,981 | Common Stock | |
| Janux Therapeutics Inc | Tighe Reardon | Acting Chief Financial Officer, Ten Percent Owner | 02 Jan 2024 | 157,000 | 157,000 | - | - | Stock Option (right to buy) | ||
| Janux Therapeutics Inc | Tighe Reardon | Acting Chief Financial Officer, Ten Percent Owner | 13 Nov 2023 | 849,854 | 849,854 | - | 5.9 | 4,988,643 | Common Stock | |
| Janux Therapeutics Inc | Tighe Reardon | Acting Chief Financial Officer, Ten Percent Owner | 03 Jan 2023 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | ||
| Janux Therapeutics Inc | Tighe Reardon | Acting Chief Financial Officer, Ten Percent Owner | 03 Jan 2022 | 116,750 | 116,750 | - | - | Stock Option (right to buy) |